<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>MMR proficient &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/mmr-proficient/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Mon, 15 Dec 2025 15:34:33 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.0</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>MMR proficient &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>Neoadjuvant Immunotherapy for Rectal Cancer: A Review</title>
		<link>https://bioengineer.org/neoadjuvant-immunotherapy-for-rectal-cancer-a-review/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Mon, 15 Dec 2025 15:34:02 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[Microsatellite stable]]></category>
		<category><![CDATA[MMR proficient]]></category>
		<category><![CDATA[Neoadjuvant immunotherapy]]></category>
		<category><![CDATA[Rectal cancer]]></category>
		<category><![CDATA[systematic review]]></category>
		<guid isPermaLink="false">https://bioengineer.org/neoadjuvant-immunotherapy-for-rectal-cancer-a-review/</guid>

					<description><![CDATA[In a groundbreaking study that could reshape the landscape of treatment for non-metastatic rectal cancer, recent findings emphasize the efficacy and safety of combining neoadjuvant therapy with immunotherapy for patients whose tumors are proficient in mismatch repair (MMR) and microsatellite stable (MSS). This systematic review and meta-analysis delves deep into the outcomes of innovative treatments, [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">308027</post-id>	</item>
	</channel>
</rss>
